Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
In June 2014, the Food and Drug Administration (FDA) issued a draft guidance document, “Internet/Social Media Platforms: Correcting Independent Third-Party Misinformation about Prescription Drugs and Medical Devices.” While the draft guidance is not legally binding, it offers insight into the FDA's expectations and issues for industry to consider as it continues to develop social media campaigns. The draft guidance indicates that the FDA will not hold responsible companies that choose to correct (or not correct) third-party misinformation. However, companies should consider the implications of whether or not to correct misinformation.
This article briefly summarizes the draft guidance and offers issues to consider. The article is not intended to make recommendations in a vacuum, as each case is fact-specific. However, it is hoped that describing the issues will allow companies to make educated decisions.
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN ENTERTAINMENT LAW.
Already a have an account? Sign In Now Log In Now
For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473
There is no efficient market for the sale of bankruptcy assets. Inefficient markets yield a transactional drag, potentially dampening the ability of debtors and trustees to maximize value for creditors. This article identifies ways in which investors may more easily discover bankruptcy asset sales.
A federal district court in Miami, FL, has ruled that former National Basketball Association star Shaquille O'Neal will have to face a lawsuit over his promotion of unregistered securities in the form of cryptocurrency tokens and that he was a "seller" of these unregistered securities.
Why is it that those who are best skilled at advocating for others are ill-equipped at advocating for their own skills and what to do about it?
Blockchain domain names offer decentralized alternatives to traditional DNS-based domain names, promising enhanced security, privacy and censorship resistance. However, these benefits come with significant challenges, particularly for brand owners seeking to protect their trademarks in these new digital spaces.
This article reviews the fundamental underpinnings of the concept of insurable interest, and certain recent cases that have grappled with the scope of insurable interest and have articulated a more meaningful application of the concept to claims under first-party property policies.